TABLE 2.
Baseline patient demographics and clinical data (n = 42)*
| MH (n = 20) | SAL (n = 22) | P | |
|---|---|---|---|
| Age (years), median (IQR) | 54 (51–64) | 54 (39–61) | 0.38 |
| Female, n | 11 (55) | 14 (64) | 0.57 |
| White, n | 19 (95) | 16 (73) | 0.06 |
| Lund-Mackay CT scorea | 8 (5–12) | 11 (7–17) | 0.05* |
| Lund-Kennedy endoscopy score | 7 (5–9) | 8 (5–10) | 0.74 |
| Nasal polyposis, n | 5 (25) | 10 (45) | 0.17 |
| Asthma, n | 7 (35) | 15 (68) | 0.03* |
| Inhalant allergies, n | 10 (50) | 8 (36) | 0.38 |
| Aspirin sensitivity, n | 1 (5) | 4 (18) | 0.19 |
| Current smoker, n | 0 (0) | 0 (0) | 1.00 |
| Oral antibiotics, n | 10 (50) | 15 (68) | 0.23 |
| Oral steroids, n | 2 (10) | 5 (23) | 0.27 |
| Topical steroid sinus irrigations, n | 15 (75) | 19 (86) | 0.35 |
| Multiple surgeries, n | 5 (25) | 8 (36) | 0.43 |
| Time to follow-up (days), median (IQR) | 37 (31–41) | 38 (30–43) | 0.70 |
*
Median (IQR) or n (%) of patients is presented.
a
Radiologic grading of sinus systems, consisting of 6 items for each nasal cavity, each scored from 0 to 2; total score recorded as the sum of all items, 0 to 24. CT = computed tomography; IQR = interquartile range; MH = manuka honey, SAL = saline.